Literature DB >> 8100597

In vitro and long-term in vivo immune dysfunction after infection of BALB/c mice with mouse hepatitis virus strain A59.

C Cray1, M O Mateo, N H Altman.   

Abstract

Mouse hepatitis virus (MHV) is a pervasive pathogen in most mouse colonies worldwide. Infection with this virus, which is often inadvertent and unrecognized, has previously been correlated in numerous anecdotal reports with immune modulation seriously affecting the outcome of biomedical experiments. Studies using experimental models to examine the effects of MHV infection have demonstrated that the virus can both stimulate and depress immune function in vitro. We have used intranasal infection of MHV-susceptible BALB/c mice with MHV strain A59 to examine the effects of this virus on lymphoid tissue composition as well as immune function both in vitro and in vivo. We observed that the thymus, spleen, and lymph nodes underwent a transient period of marked cellular depletion. During that time, the percentages of T and B cells in the spleen remained normal. However, within 1 week after inoculation, splenic lymphoid cell proliferation was significantly decreased in response to the T-cell stimuli, concanavalin A and anti-CD3 monoclonal antibody. This continued through day 35 but was resolved by 102 days postinoculation. Notably, at days 35 and 102, mice infected with MHV-A59 were unable to reject skin grafts at a rate comparable to normal animals. These results support a basis for in vitro and, importantly, long-term in vivo immune dysfunction after infection with MHV.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8100597

Source DB:  PubMed          Journal:  Lab Anim Sci        ISSN: 0023-6764


  10 in total

Review 1.  Natural pathogens of laboratory mice, rats, and rabbits and their effects on research.

Authors:  D G Baker
Journal:  Clin Microbiol Rev       Date:  1998-04       Impact factor: 26.132

2.  Targeted disruption of the Ceacam1 (MHVR) gene leads to reduced susceptibility of mice to mouse hepatitis virus infection.

Authors:  D M Blau; C Turbide; M Tremblay; M Olson; S Létourneau; E Michaliszyn; S Jothy; K V Holmes; N Beauchemin
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

3.  Specific T-cell response correlates with resistance of genetic heterogeneous mouse populations to mouse hepatitis virus 3 infection.

Authors:  R C Vassão; W H Cabrera; O C Ibanez; C A Pereira
Journal:  Arch Virol       Date:  1995       Impact factor: 2.574

4.  Receptor-dependent coronavirus infection of dendritic cells.

Authors:  Brian C Turner; Erin M Hemmila; Nicole Beauchemin; Kathryn V Holmes
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

5.  Effects of fenbendazole on routine immune response parameters of BALB/c mice.

Authors:  Carolyn Cray; David Villar; Julia Zaias; Norman H Altman
Journal:  J Am Assoc Lab Anim Sci       Date:  2008-11       Impact factor: 1.232

6.  Thymus involution induced by mouse hepatitis virus A59 in BALB/c mice.

Authors:  C Godfraind; K V Holmes; J P Coutelier
Journal:  J Virol       Date:  1995-10       Impact factor: 5.103

7.  Granulomatous peritonitis and pleuritis in interferon-gamma gene knockout mice naturally infected with mouse hepatitis virus.

Authors:  M P France; A L Smith; R Stevenson; S W Barthold
Journal:  Aust Vet J       Date:  1999-09       Impact factor: 1.281

Review 8.  Of Mice and Men: The Coronavirus MHV and Mouse Models as a Translational Approach to Understand SARS-CoV-2.

Authors:  Robert W Körner; Mohamed Majjouti; Miguel A Alejandre Alcazar; Esther Mahabir
Journal:  Viruses       Date:  2020-08-12       Impact factor: 5.048

9.  Mouse hepatitis virus infection of mice causes long-term depletion of lactate dehydrogenase-elevating virus-permissive macrophages and T lymphocyte alterations.

Authors:  C Even; R R Rowland; P G Plagemann
Journal:  Virus Res       Date:  1995-12       Impact factor: 3.303

Review 10.  Immunopathological aspects of coronavirus infections.

Authors:  H Wege
Journal:  Springer Semin Immunopathol       Date:  1995
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.